MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clml.2024.02.007

Медицинская библиотека · Clinical lymphoma, myeloma & leukemia · 2024

Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Yamshon Samuel, Gribbin Caitlin, Alhomoud Mohammad, Chokr Nora, Chen Zhengming, Demetres Michelle, Pasciolla Michelle, Leonard John, Shore Tsiporah, Martin Peter

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

BACKGROUND

The application of CD19-directed chimeric antigen receptor T (CAR T) cell therapy has improved outcomes for thousands of patients with non-Hodgkin B cell lymphoma (NHL). The toxicities associated with various CAR T cell products, however, can be severe and difficult to anticipate.

METHODS

In this systematic review and meta-analysis, we set out to determine whether there are measurable differences in common toxicities, including cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS), cytopenias, and infections, between CAR T products that are commercially available for the treatment of NHL.

RESULTS

After a stringent study selection process, we used a cohort of 1364 patients enrolled in 15 prospective clinical trials investigating the use of axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel). We found that the rates of CRS and ICANS were significantly higher with axi-cel as compared to both liso-cel and tisa-cel. Conversely, we demonstrated that rates of all-grade and severe neutropenia were significantly greater with liso-cel. Febrile neutropenia and all-grade infection rates did not differ significantly between products though rates of severe infection were increased with axi-cel.

CONCLUSIONS

Overall, this study serves as the first to delineate toxicity profiles associated with various available CAR T products. By better understanding associated toxicities, it may become possible to tailor therapies towards individual patients and anticipate the development of toxicities at earlier stages.

Для цитирования: Yamshon Samuel, Gribbin Caitlin, Alhomoud Mohammad, Chokr Nora, Chen Zhengming, Demetres Michelle, Pasciolla Michelle, Leonard John, Shore Tsiporah, Martin Peter. Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.. Clinical lymphoma, myeloma & leukemia. 2024. DOI: 10.1016/j.clml.2024.02.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.